About WuXi AppTec
WuXi AppTec is a company based in Shanghai (China) founded in 2000. WuXi AppTec has raised $40 million across 5 funding rounds from investors including General Atlantic, Warburg Pincus and Eight Roads Ventures. The company has 1,681 employees as of December 31, 2022. WuXi AppTec has completed 10 acquisitions, including Abgent, Ambrx and Crelux. WuXi AppTec operates in a competitive market with competitors including Eurofins Scientific, Ipsen, ANI Pharmaceuticals, Red Nucleus and Aptar, among others.
- Headquarter Shanghai, China
- Employees 1681 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
$8.27 M (USD)-3as on Dec 31, 2023
-
Net Profit
-$9.82 M (USD)48as on Dec 31, 2023
-
EBITDA
Not available
-
Total Equity Funding
$40 M (USD)
in 5 rounds
-
Latest Funding Round
$15.88 M (USD), Post-IPO
Apr 02, 2021
-
Investors
General Atlantic
& 4 more
-
Employee Count
1681
as on Dec 31, 2022
-
Investments & Acquisitions
Abgent
& 9 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of WuXi AppTec
Unlock access to complete
Leadership Team
25 people
Software Development Team
25 people
Sales and Marketing
15 people
Human Resources and Administration
15 people
Operations Team
7 people
Senior Team
5 people
Legal and Compliance
4 people
Creative and Marketing Team
3 people
Unlock access to complete
Funding Insights of WuXi AppTec
WuXi AppTec has successfully raised a total of $40M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $15.88 million completed in April 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in WuXi AppTec
WuXi AppTec has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include General Atlantic, Warburg Pincus and Eight Roads Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multi-stage private equity investments are pursued across diverse sectors.
|
Locked | Locked | Locked | |
|
Venture capital investment and global platform support for startups.
|
Locked | Locked | Locked | |
|
Private equity fund focused on global markets
|
Locked | Locked | Locked |
Investor details for WuXi AppTec
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by WuXi AppTec
WuXi AppTec has strategically engaged in corporate development activities, having acquired 10 companies. Notable acquisitions include Abgent, Ambrx and Crelux.
Investment portfolio details for WuXi AppTec
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Drug quality control solutions are provided for pharmaceuticals.
|
Locked | Locked | 2018 | Locked | |
|
Genomics platform for clinical insights and rapid diagnoses is provided.
|
Locked | Locked | 2013 | Locked | |
|
Integrated silicon photonics products are developed for optical communication applications.
|
Locked | Locked | 2013 | Locked |
Complete acquisition details for WuXi AppTec
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - WuXi AppTec
Detailed financials for WuXi AppTec
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Wuxi Apptec Comparisons
Peer comparison for WuXi AppTec
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of WuXi AppTec
WuXi AppTec operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Eurofins Scientific, Ipsen, ANI Pharmaceuticals, Red Nucleus and Aptar, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Laboratory testing and contract research services are provided globally.
|
|
| Locked | Locked | Locked |
Biopharmaceutical company focused on developing and commercializing innovative treatments in oncology, rare disease, and neuroscience to improve patient health outcomes
|
|
| Locked | Locked | Locked |
Branded and generic prescription drugs are developed, manufactured, and marketed.
|
|
| Locked | Locked | Locked |
Advisory, scientific, and medical communications provided for pharmaceutical industry.
|
|
| Locked | Locked | Locked |
Regulatory support, brand differentiation, and prototyping services are provided.
|
Detailed competitors of WuXi AppTec
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Wuxi Apptec
Complete news archive for WuXi AppTec
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about WuXi AppTec
WuXi AppTec was founded in 2000 and raised its 1st funding round 7 years after it was founded.
WuXi AppTec is headquartered in Shanghai, China.
WuXi AppTec is a funded company, having raised a total of $40M across 5 funding rounds to date.
As of Dec 31, 2022, the latest employee count at WuXi AppTec is 1,681.
Annual revenue of WuXi AppTec is $8.27M as on Dec 31, 2023.
WuXi AppTec is a provider of a suite of CRO and CDMO services for small molecules, biologics, and medical devices. It offers a suite of services for the research, development, and manufacturing of both small molecules and biologics and also caters to medical device development and has operations all over the globe. They provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device RD process. The company built its initial capabilities around discovery chemistry and has further enhanced the integrated services with analytical services, bio-analytical services, process research, process development services, API manufacturing services, DMPKADME, discovery biology, pharmacology, formulation, toxicology, genomic services, biologics manufacturing services, antibody, and biological research reagent manufacturing and sales, and most recently clinical research and regulatory services. In 2022, the company recorded annual revenues of 5.84B and a net profit of 1.31B.
WuXi AppTec's top competitors include ANI Pharmaceuticals, Aptar and CHEPLAPHARM.
WuXi AppTec has 5 investors. Key investors include General Atlantic, Warburg Pincus, Eight Roads Ventures, Ping An Bank, and 120 Capital Management.